

New Oral Anticoagulants

Drug	FDA Indication	Dose
Dabigatran Pradaxa®	<ul style="list-style-type: none"> Stroke prevention in pts with non-valvular a-fib 	<p>Usual Dose: 150 mg po BID</p> <p>Renal Dosing</p> <ul style="list-style-type: none"> CrCl 15-30 ml/min: 75 mg po BID CrCl <15 ml/min or HD: avoid use CrCl 30-50 ml/min: 75 mg BID if concomitant use dronedarone or systemic ketoconazole. <p>Conversions</p> <ul style="list-style-type: none"> From <i>warfarin</i> to <i>dabigatran</i> <ul style="list-style-type: none"> d/c warfarin, start dabigatran when INR <2 From <i>dabigatran</i> to <i>warfarin</i> <ul style="list-style-type: none"> CrCl ≥50 ml/min: Start warfarin 3 days before d/c dabigatran CrCl 30-50 ml/min: Start warfarin 2 days before d/c dabigatran CrCl 15-30 ml/min: Start warfarin 1 day before d/c dabigatran
Rivaroxaban Xarelto® **Administer with food**	<ul style="list-style-type: none"> Stroke prevention in patients with non-valvular a-fib Treatment of DVT and PE DVT prophylaxis post hip or knee surgery 	<p>Usual Dose:</p> <ul style="list-style-type: none"> Stroke prevention in afib <ul style="list-style-type: none"> CrCl > 50 ml/min: 20mg po q day with evening meal CrCl 15-50 ml/min: 15mg po q day CrCl <15 ml/min: avoid use Treatment of DVT/PE <ul style="list-style-type: none"> Initial: 15 mg BID X 21 days, then switch to maintenance dose Maintenance: 20 mg q day CrCl <30 ml/min: avoid use <p>Conversions:</p> <ul style="list-style-type: none"> From <i>warfarin</i> to <i>rivaroxaban</i> <ul style="list-style-type: none"> d/c warfarin; start rivaroxaban when INR < 3 From <i>rivaroxaban</i> to <i>warfarin</i> <ul style="list-style-type: none"> Start warfarin and a parenteral anticoagulant at time of rivaroxaban next dose
Apixaban Eliquis®	<ul style="list-style-type: none"> Stroke prevention in patients with non-valvular a-fib 	<p>Usual Dose:</p> <ul style="list-style-type: none"> 5 mg po BID Reduce dose to 2.5 mg BID in patients with any 2 of the following: <ul style="list-style-type: none"> Weight: ≤60 kg SCr ≥ 1.5 ≥80 yrs old <p>Conversions:</p> <ul style="list-style-type: none"> From <i>warfarin</i> to <i>apixaban</i> <ul style="list-style-type: none"> d/c warfarin; start apixaban when INR < 2 From <i>apixaban</i> to <i>warfarin</i> <ul style="list-style-type: none"> d/c apixaban; start warfarin and a parenteral anticoagulant at time of apixaban next dose

References:

- Pradaxa® [Package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc, April 2013.
- Xarelto® [Package insert]. Titusville, NJ: Janssen Pharmaceuticals. August 2013.
- Eliquis® [Package insert]. Princeton, NJ: Bristol-Myers Squibb Company. December 2012.